tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Galapagos NV to Wind Down Cell Therapy Business Following Strategic Review

Story Highlights
  • Galapagos NV plans to wind down its cell therapy business to focus on transformational business development.
  • The wind-down will affect 365 employees and involve significant restructuring costs through 2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Galapagos NV to Wind Down Cell Therapy Business Following Strategic Review

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Galapagos ( (GLPG) ) has shared an announcement.

On October 21, 2025, Galapagos NV announced its intention to wind down its cell therapy business following a comprehensive strategic review. This decision, aimed at enhancing operational efficiencies and focusing on transformational business development, was unanimously approved by the board, excluding two directors from Gilead who recused themselves. The wind-down process is expected to impact approximately 365 employees and result in the closure of several sites across Europe, the U.S., and China. The company plans to allocate its resources to areas of unmet need, with anticipated costs ranging from €100 million to €125 million in operating expenses and €150 million to €200 million in restructuring costs through 2026.

The most recent analyst rating on (GLPG) stock is a Sell with a $22.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

Galapagos’ overall stock score is primarily impacted by its financial performance, which is currently weak due to significant profitability and cash flow challenges. The technical analysis provides some positive momentum, but the overbought conditions suggest caution. The valuation is unattractive due to negative earnings and lack of dividends. These factors collectively result in a moderate overall score.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos NV is a biotechnology company based in Mechelen, Belgium, primarily engaged in the development of novel therapeutics. The company focuses on leveraging its cash resources to build a pipeline of innovative treatments through strategic business development transactions.

Average Trading Volume: 270,045

Technical Sentiment Signal: Hold

Current Market Cap: $2.27B

For detailed information about GLPG stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1